Page last updated: 2024-08-24

imiquimod and Melanoma

imiquimod has been researched along with Melanoma in 138 studies

Research

Studies (138)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.72)18.2507
2000's47 (34.06)29.6817
2010's65 (47.10)24.3611
2020's25 (18.12)2.80

Authors

AuthorsStudies
Bonnet, PA; Bressolle, F; David, N; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Khier, S; Moarbess, G; Pinguet, F1
Carvajal, R; Khan, S; Levin, M; Satish, T; Yoon, AJ1
Bevilacqua, F; Bleeker, MCG; Bornstein, J; Carcopino, X; Chargari, C; Cruickshank, ME; Erzeneoglu, BE; Esat Temiz, B; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kesic, V; Planchamp, F; Preti, M; Querleu, D; Reich, O; Stockdale, CK; Van Beurden, M; Vieira-Baptista, P; Woelber, L; Zodzika, J1
Bevilacqua, F; Bleeker, MCG; Bornstein, J; Carcopino, X; Chargari, C; Cruickshank, ME; Erzeneoglu, BE; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kesic, V; Planchamp, F; Preti, M; Querleu, D; Reich, O; Stockdale, CK; Temiz, BE; Van Beurden, M; Vieira-Baptista, P; Woelber, L; Zodzika, J1
Daniel, C; Kaushik, M; Neumann, I; Patalay, R; Timlin, H1
Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Qian, C; Ren, H; Tao, X; Wang, A; Yang, Z1
Cen, L; Chen, X; Chu, Y; Dai, H; Feng, X; Huang, S; Ke, Y; Liu, B; Liu, Q; Qian, X; Zhang, Z1
Caimi, AT; Morilla, MJ; Perez, AP; Ramirez, C; Romero, EL1
Katyal, P; Lynch, KT; Meneveau, MO; Olson, WC; Slingluff, CL; Tran, CA1
Carr, M; Correa, L; Culbreth, A; Cunningham, K; DePalo, DK; Harkins, A; Longbottom, B; Patel, N; Puleo, C; Reed, R; Seminario-Vidal, L; Ward, C; Zager, JS1
Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL1
Barton, VR; Cheng, MY; Kao, J; Kirane, AR; Kiuru, M; Ma, C; Maverakis, E; Petukhova, TA; Wang, EA1
Choi, JN; Shetty, A; Sosman, J; Sunshine, JC1
Asinari, J; Feliciani, C; Goldust, M; Lotti, T; Pedrazzi, G; Satolli, F; Zucchi, A1
Dika, E; Lambertini, M; Melotti, B; Patrizi, A; Ravaioli, GM; Scarfì, F; Veronesi, G1
Frank, LA; Gazzi, RP; Guterres, SS; Onzi, G; Pohlmann, AR1
Abadir, W; Alavi, N; Look Hong, NJ; Nadler, A; Wright, FC1
Dika, E; Lambertini, M; Melotti, B; Mussi, M; Patrizi, A; Scarfì, F; Tartari, F; Veronesi, G1
Hignett, E; Khachemoune, A; Nguyen, K1
Chambers, M; Chapman, MS; O'Hern, K; Ryan, C1
Benedetto, C; Bertero, L; Bevilacqua, F; Borella, F; Carosso, AR; Cassoni, P; Castellano, I; Collemi, G; Cosma, S; Gallio, N; Micheletti, L; Preti, M1
Gesing, M; Hlebowicz, M; Iżycka-Świeszewska, E; Nowicki, RJ; Sikorska, M; Smiatacz, T; Sobjanek, M; Sokołowska-Wojdyło, M; Sławińska, M1
Basehore, BM; Globerson, JA; Nessel, T; Saleeby, ER1
Chianese-Bullock, KA; Deacon, D; Grosh, WW; Lynch, KT; Meneveau, MO; Olson, WC; Patterson, JW; Petroni, GR; Salerno, EP; Slingluff, CL; Smolkin, M; Woodson, E1
Chapman, MS; Park, AJ; Paul, J; Samie, FH1
Lv, R; Sun, Q1
Aranda Lopez, P; Freichel, M; Hartmann, AK; Radsak, MP; Schild, H; Stassen, M; Zajac, M1
Schwarz, T; Wehkamp, U1
Read, T; Schaider, H; Smithers, BM; Soyer, HP; Thomas, J; Wagels, M; Webber, S1
Cheng, MY; Kirane, A; Kulkarni, R; Luxardi, G; Ma, C; Maverakis, E; Monjazeb, AM; Ogawa, H1
Casanova, JM; García-de-la-Fuente, MR; Gatius, S; Huerva, V; Martí, RM; Matas-Nadal, C; Ortega, E; Sòria, X; Vilardell, F1
Arnaiz, B; Bocanegra Gondan, AI; Cobaleda-Siles, BM; Escors, D; García-Granda, MJ; Gato, M; Gómez Blanco, N; Llop, J; Mareque-Rivas, JC; Padro, D; Ruiz-de-Angulo, A; Zabaleta, A1
Delman, KA; Farley, CR; Lopez-Aguiar, AG; Lowe, MC; Oh, G; Russell, MC1
Alfano, R; Argenziano, G; Corneli, P; DI Brizzi, EV; Donadio, C; Moscarella, E; Zalaudek, I1
Calonje, E; Craythorne, E; Lewis, F; Nath, R; Veraitch, O1
Caruntu, C; Constantin, MM; Draghici, CC; Lisievici, CV; Lupu, M; Popa, AV; Sebe, TI; Solomon, I; Vajaitu, C; Voiculescu, VM1
Hsia, HC; Kim, S; Narayan, D; Norwich-Cavanaugh, A; Tsay, C1
Bassukas, IM; Gaitanis, G1
Halpern, AC; Quigley, EA1
Bajek, A; Czajkowski, R; Drewa, T; Schwartz, RA; Uzarska, M; Zegarska, B1
Banzhaf, CA; Jemec, GB; Mogensen, M; Ring, HC; Themstrup, L1
Cohen, DN; Johnson, DB; Joseph, RW; Kelley, MC; Likhari, SS; Powers, JG; Shinn, L; Sosman, JA; Wallender, EK; Zwerner, JP1
Bourgault-Villada, I; Clerici, T; Elfatoiki, FZ; Longvert, C; Roudier-Pujol, C; Saiag, P; Vasseur, E1
Chen, YJ; Huang, SW; Kao, JK; Lee, HC; Liang, SM; Shieh, JJ; Wang, ST; Wu, CY1
Fields, J; Fields, K; Jewell, T; Milikowski, C1
Aspord, C; Charles, J; Leccia, MT; Leloup, C; Molens, JP; Plumas, J; Tramcourt, L1
Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y1
Hanlon, A; Lazova, R; Narayan, D; Sue, GR1
Costa, C; Mascolo, M; Palmisano, F; Russo, D; Scalvenzi, M1
D'Errico, A; De Giorgi, V; Gori, A; Grazzini, M; Massi, D; Papi, F; Savarese, I; Vannucchi, M1
Annessi, G; Didona, B; Didona, D; Napolitano, M1
Khaiboullina, SF; Lombardi, VC; Rizvanov, AA1
Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T1
Ariyan, S; Choi, JN; Geiger, EJ; Narayan, D; Pandit, AS1
Oranges, CM; Sisti, A; Sisti, G1
Chen, YJ; Chen, YY; Huang, SW; Kao, JK; Liang, SM; Shieh, JJ; Wang, ST; Wu, CY1
Chen, FW; Egbert, BM; Kim, DD; Swetter, SM1
Galan, A; Higgins, HW; Lee, KC; Leffell, DJ1
Barrio, MM; Mordoh, J; Pizzurro, GA; Podhajcer, OL; Sganga, L; Tapia, IJ1
Burrall, BA; Christensen, SD; Fitzmaurice, SD; Fung, MA; Garcia, MS; Joo, J; King, B; Konia, T; Leventhal, J; Martinez, S; Maverakis, E; Monjazeb, AM; Patel, F; Shi, VY; Tran, K; Wilken, R1
Abd Elmageed, ZY; Brodell, RT; El-Khattouti, A; Haikel, Y; Hannig, M; Hassan, M; Hassan, SY; Kandil, E; Leverkus, M; Megahed, M; Selimovic, D; Taylor, EB1
Baradad, M; Martí, R; Nagore, E; Ortiz-Brugués, A; Requena, C; Rivas-Tolosa, N; Sanmartín, V; Soriano, V; Toledo-Pastrana, T; Traves, V1
Chang, SE; Lee, MW; Lee, YJ; Rhee, do Y; Won, CH; Won, KH1
Bagaria, S; Cappel, M; Gilstrap, C; Jambusaria-Pahlajani, A; Joseph, RW; Swaika, A; Tzou, K1
Chianese-Bullock, KA; Clark, RA; Deacon, DH; Galeassi, N; Marincola, FM; Mauldin, IS; Mullins, DW; Olson, WC; Petroni, GR; Slingluff, CL; Smith, KT; Smolkin, ME; Stowman, AM; Teague, JE; Wages, NA; Wang, E1
Grady, BE; Spencer, JM1
Gioia Di Chiacchio, N; Haneke, E; le Voci, F; Ocampo-Garza, J; Paschoal, FM1
Brodland, DG; Murphy, ME; Zitelli, JA1
Adams, S; Angiulli, A; Angiulli, F; Berman, RS; Berner, N; Bhardwaj, N; Chiriboga, L; Cruz, CM; Gnjatic, S; Hardin, E; Hoffman, EW; Holman, RM; Jungbluth, A; Manches, O; Nonaka, D; O'Neill, DW; Old, L; Pan, L; Pavlick, AC; Ritter, E; Shao, Y; Shapiro, RL; Siu, K; Venhaus, RR1
Belonwu, N; Bodman-Smith, MD; Dalgleish, AG; Fischer, MD; Green, DS1
Harth, W; Heber, G; Helbig, D; Pönitzsch, I; Simon, JC; Wetzig, T1
Eickenscheidt, L; Kowalzick, L1
Fosko, SW; Missall, TA1
Uhara, H1
Dengel, LT; Grosh, WW; Harris, RC; Patterson, JW; Slingluff, CL; Turza, K; White, K1
Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I1
Bos, JD; Filippov, DV; Konijnenberg, D; Luiten, RM; Meeuwenoord, NJ; Melief, CJ; Picavet, DI; Tjin, EP; van den Boorn, JG; van der Veen, JP1
Erickson, C; Miller, SJ1
Ma, F; Zhang, C; Zhang, J1
Crawford, RI; Sadownik, LA1
Fosko, SW; Hurley, MY; Missall, TA1
Parlette, EC; Toren, KL1
Aires, D; Dusing, R; Meggison, A; Miller, AK1
Chen, SL; Fung, MA; Garcia, MS; Goodarzi, H; Martinez, SR; Maverakis, E; Miyamura, Y; Ono, Y; Phan, T; Wehrli, LN1
Botella-Estrada, R; Nagore, E1
Borden, E; Triozzi, PL; Tuthill, RJ1
Caminal, JM; Fabra, A; Ferreres, JR; Marcoval, J; Penín, RM; Piulats, JM1
Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S1
Coyner, K; Loeffler, D1
Bentow, JJ; Bruhn, KW; Chang, PL; Comin-Anduix, B; Craft, N; Dauphine, C; Economou, JS; Greger, S; Haskell, J; Konishi, T; Lee, DK; Moy, L; Narayan, R; Nguyen, H; Ribas, A; Tsui, S; Vanchinathan, V; Vargas, HI1
Barbosa, VH; Beutner, KR; Bhushan, R; Bichakjian, CK; Chuang, TY; Duvic, M; Foote Hood, A; Grichnik, JM; Halpern, AC; Ho, VC; Johnson, TM; Smith Begolka, W; Sober, AJ; Swetter, SM; Tsao, H1
Bogatch, K; Carvajal, RD; Chapman, PB; Chi, DS; Costantino, PD; Flavin, M; Gardner, GJ; Pulitzer, MP; Schwartz, GK; Smyth, EC; Wolchok, JD1
Glaser, A; Kalb, ML; Koszik, F; Stary, G; Stingl, G1
Amberg, N; Colonna, M; Drobits, B; Grundtner, R; Hammer, M; Holcmann, M; Sibilia, M; Swiecki, M1
Cohen, JL; Ellis, LZ; High, W; Stewart, L1
Arbiser, JL; Bips, M; Bonner, MY; Kovach, C; Seidler, A1
Bachmann, MF; Baumgaertner, P; Dummer, R; Geldhof, C; Goldinger, SM; Hammann-Haenni, A; Kündig, TM; Michielin, O; Mihic-Probst, D; Prior, JO; Schwarz, K; Speiser, DE; Willers, J1
Moon, SD; Spencer, JM1
Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Wagner, A1
Bong, AB; Bonnekoh, B; Franke, I; Gollnick, H; Schön, M; Ulrich, J1
Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH1
Awada, A; Heenen, M; Laporte, M; Mathieu, A; Petein, M; Velu, T; Vereecken, P1
Fisher, GH; Lang, PG1
Beyeler, M; Burg, G; Dummer, R; Morcinek, J1
Kerl, H; Kopera, D; Richtig, E; Wolf, IH1
Beiteke, U; Grabbe, S; Loquai, C; Luger, TA; Metze, D; Nashan, D; Rüping, KW1
Bignon, YJ; Chèvenet, C; Corbin-Duval, A; D'Incan, M; Déchelotte, P; Franck, F; Hesling, C; Madelmont, JC; Mansard, S; Souteyrand, P; Veyre, A1
Bong, AB; Drewniok, C; Eberle, J; Geilen, CC; Gollnick, H; Schön, M; Schön, MP; Wienrich, BG1
Leverkus, M1
Schön, M; Schön, MP1
Holcmann, M; Lührs, P; Meindl, S; Palamara, F; Sibilia, M; Stingl, G1
Huntley, A; Navi, D1
Astner, S; Curiel-Lewandrowski, C; Frankenthaler, RA; González, S; Swindells, KJ; Tahan, SR; Williams, CM1
Caron, D; Cebon, J; Chen, Q; Chen, W; Davis, ID; Dimopoulos, N; Hopkins, W; Jackson, H; Jefford, M; Maraskovsky, E; Masterman, KA; Parente, P; Shackleton, M; Tai, T1
Martín-García, RF; Muñoz, CM; Sánchez, JL1
Skinner, R1
Dummer, R; Urosevic, M1
Cheney, RT; Dawson, K; Zeitouni, NC1
Bieber, T; Haller, O; Tueting, T; Uerlich, M; Wenzel, J1
Grant-Kels, JM; Grin, CM; Kluk, M; Ray, CM1
Marincola, FM; Monsurró, V; Panelli, MC; Wang, E1
Botella-Estrada, R; Guillén, C; Nagore, E; Sanmartín, O1
Casado, M; González-Beato, M; Mayor, M; Miralles, L; Pizarro, A; Sigüenza, M; Vidaurrázaga, C1
Sondak, VK1
Cartwright, N; Coyle, A; Fitzgerald, KA; Mitchell, JA; Silverman, N1
Cruickshank, DJ; Lonsdale-Eccles, AA; Morgan, JM; Nagarajan, S1
Figl, R; Goerdt, S; Hildenbrand, R; Kettelhack, C; Schadendorf, D; Thoelke, A; Ugurel, S; Utikal, J; Zimpfer, A1
Chen, WR; Naylor, MF; Nordquist, RE; Perry, LA; Teague, TK1
Bug, R; Gille, J; Kaufmann, R; Kovács, A; Spieth, K; Wolter, M1
Bodman-Smith, MD; Dalgleish, AG; Fischer, MD; Green, DS1
Cerroni, L; Kerl, H; Kodama, K; Wolf, IH1
Choi, GS; Lee, JR; Park, JH; Shin, JH; Song, SU1
Fenske, NA; Glass, LF; Prakash, AV; Shistik, G1
Alkan, SS; Dumitru, CD; Gibson, SJ; Inglefield, JR; Larson, CJ; Lipson, KE; Tomai, MA; Vasilakos, JP1
Gore, ME; Horton, V; Moore, J; Owens, M; Savage, P; Witt, P1
Funk, JO; Schuler, G; Steinmann, A; von den Driesch, P1
Hengge, U1

Reviews

26 review(s) available for imiquimod and Melanoma

ArticleYear
Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
    Eye (London, England), 2023, Volume: 37, Issue:3

    Topics: Aminoquinolines; Eyelids; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Skin Neoplasms

2023
Topical treatments for skin cancer.
    Advanced drug delivery reviews, 2020, 01-01, Volume: 153

    Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; Diterpenes; Drug Delivery Systems; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis, Actinic; Melanoma; Neoplasms, Squamous Cell; Photochemotherapy; Retinoids; Skin; Skin Neoplasms; Ultraviolet Rays

2020
The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Retrospective Studies; Skin Neoplasms

2020
Current and emerging treatment options for metastatic melanoma: a focused review.
    Dermatology online journal, 2020, Jul-15, Volume: 26, Issue:7

    Topics: Antineoplastic Agents; B7-H1 Antigen; Cancer Vaccines; CTLA-4 Antigen; Humans; Imiquimod; Interferons; Ipilimumab; Melanoma; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Radiotherapy; Survival Rate

2020
Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.
    International journal of molecular sciences, 2020, Dec-27, Volume: 22, Issue:1

    Topics: Adjuvants, Immunologic; Alphapapillomavirus; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Neuroendocrine Tumors; Paget Disease, Extramammary; Prognosis; Vulvar Neoplasms

2020
A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment.
    Journal of cellular biochemistry, 2017, Volume: 118, Issue:11

    Topics: Aminoquinolines; Cryotherapy; Fluorouracil; Humans; Imiquimod; Melanoma; Photochemotherapy; PubMed; Skin Neoplasms

2017
Mediators of Inflammation in Topical Therapy of Skin Cancers.
    Mediators of inflammation, 2019, Volume: 2019

    Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cytokines; Diterpenes; Fluorouracil; Humans; Imiquimod; Inflammation; Melanoma; Neoplasm Metastasis; Skin; Skin Neoplasms; Toll-Like Receptor 7

2019
Microinvasive melanoma: cutaneous pharmacotherapeutic approaches.
    American journal of clinical dermatology, 2013, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Dicarboxylic Acids; Female; Fluorouracil; Geriatric Assessment; Humans; Imiquimod; Immunohistochemistry; Interferon-alpha; Male; Melanoma; Neoplasm Invasiveness; Pharmaceutical Preparations; Prognosis; Risk Assessment; Skin Neoplasms; Survival Analysis; Treatment Outcome

2013
Chemoprevention of skin melanoma: facts and myths.
    Melanoma research, 2013, Volume: 23, Issue:6

    Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Chemoprevention; Curcumin; Flavonoids; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Pigmentation; Randomized Controlled Trials as Topic; Resveratrol; Retinoids; Risk; Skin; Skin Neoplasms; Stilbenes; Tea; Treatment Outcome; Vitamin D

2013
Localized diffuse melanosis associated with melanoma successfully treated with imiquimod cream 5%: a case report and review of the literature.
    Cutis, 2014, Volume: 93, Issue:3

    Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Melanosis; Skin Neoplasms

2014
Melanoma of the glans penis successfully treated with topical imiquimod: dermoscopy usefulness in clinical monitoring and review of the literature.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2017, Volume: 152, Issue:6

    Topics: Administration, Cutaneous; Adult; Aminoquinolines; Antineoplastic Agents; Dermoscopy; Humans; Imiquimod; Male; Melanoma; Penile Neoplasms; Skin Neoplasms; Treatment Outcome

2017
Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    European journal of clinical investigation, 2015, Volume: 45 Suppl 1

    Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Dendritic Cells; Disease Progression; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasms; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Toll-Like Receptors; Tumor Escape; Tumor Microenvironment

2015
Interventions for melanoma in situ, including lentigo maligna.
    The Cochrane database of systematic reviews, 2014, Dec-19, Issue:12

    Topics: Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Melanoma, Cutaneous Malignant; Nicotinic Acids; Randomized Controlled Trials as Topic; Skin Neoplasms

2014
Topical treatment of melanoma skin metastases with imiquimod: a review.
    Dermatology online journal, 2015, 02-15, Volume: 21, Issue:2

    Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Humans; Imiquimod; Melanoma; Skin Cream; Skin Neoplasms; Treatment Outcome

2015
Melanoma in situ: Part II. Histopathology, treatment, and clinical management.
    Journal of the American Academy of Dermatology, 2015, Volume: 73, Issue:2

    Topics: Administration, Topical; Aminoquinolines; Biopsy, Needle; Carcinoma in Situ; Female; Humans; Imiquimod; Immunohistochemistry; Immunotherapy; Injections, Intralesional; Interferon-alpha; Laser Therapy; Male; Melanoma; Melanoma, Cutaneous Malignant; Mohs Surgery; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Treatment Outcome

2015
Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
    International journal of dermatology, 2010, Volume: 49, Issue:5

    Topics: Aminoquinolines; Antineoplastic Agents; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Mohs Surgery; Skin Neoplasms; Treatment Outcome

2010
Managing melanoma in situ.
    Seminars in cutaneous medicine and surgery, 2010, Volume: 29, Issue:4

    Topics: Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Laser Therapy; Melanoma; Mohs Surgery; Skin Neoplasms

2010
[Imiquimod in the treatment of lentigo maligna].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:8

    Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Contraindications; Cryotherapy; Disease Progression; Drug Approval; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Microscopy, Confocal; Mohs Surgery; Neoplasm Invasiveness; Skin Neoplasms; Treatment Outcome

2011
[Cutaneous neoplasms].
    Praxis, 2003, Sep-03, Volume: 92, Issue:36

    Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Cryotherapy; Diagnosis, Differential; Female; Fluorouracil; Hemangiosarcoma; HIV Infections; Humans; Imiquimod; Immunotherapy; Keratosis; Lymph Node Excision; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Neoplasm Recurrence, Local; Photochemotherapy; Randomized Controlled Trials as Topic; Sarcoma, Kaposi; Skin; Skin Neoplasms; Time Factors

2003
Imiquimod: unexpected killer.
    The Journal of investigative dermatology, 2004, Volume: 122, Issue:5

    Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Humans; Imiquimod; Melanoma; Skin Neoplasms

2004
Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
    Apoptosis : an international journal on programmed cell death, 2004, Volume: 9, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Basal Cell; Caspases; Cytochrome c Group; Enzyme Activation; Humans; Imiquimod; Melanoma; Mitochondria; Models, Biological; Neoplasms; Ointments; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Vascular Neoplasms

2004
Imiquimod 5 percent cream and the treatment of cutaneous malignancy.
    Dermatology online journal, 2004, Jul-15, Volume: 10, Issue:1

    Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Clinical Trials as Topic; Condylomata Acuminata; Drug Screening Assays, Antitumor; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Immunity, Cellular; Immunologic Factors; Keratoacanthoma; Keratosis; Male; Melanoma; Multicenter Studies as Topic; Mycosis Fungoides; Ointments; Paget Disease, Extramammary; Precancerous Conditions; Randomized Controlled Trials as Topic; Skin Neoplasms

2004
Role of topical therapies in the management of cutaneous disease.
    Journal of cutaneous medicine and surgery, 2004, Volume: 8 Suppl 3

    Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Dermatitis, Atopic; Dermatitis, Seborrheic; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Toll-Like Receptors

2004
Role of imiquimod in skin cancer treatment.
    American journal of clinical dermatology, 2004, Volume: 5, Issue:6

    Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Imiquimod; Immunologic Factors; Melanoma; Skin Neoplasms

2004
A global approach to tumor immunology.
    Cellular & molecular immunology, 2004, Volume: 1, Issue:4

    Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; Combined Modality Therapy; Gene Expression Profiling; Genomics; Humans; Imiquimod; Immune System; Immunologic Surveillance; Immunotherapy; Inflammation; Interleukin-2; Melanoma; Neoplasms; T-Lymphocytes

2004
[Topical treatment of melanoma skin metastases with imiquimod].
    Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:2

    Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms

2005

Trials

12 trial(s) available for imiquimod and Melanoma

ArticleYear
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
    Journal for immunotherapy of cancer, 2021, Volume: 9, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Adolescent; Adult; Aged; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Freund's Adjuvant; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imiquimod; Immunogenicity, Vaccine; Injections, Intradermal; Injections, Subcutaneous; Lipids; Male; Melanoma; Melanoma-Specific Antigens; Middle Aged; Skin Neoplasms; Time Factors; Toll-Like Receptor 7; Treatment Outcome; Vaccination; Vaccines, Subunit; Young Adult

2021
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
    BMJ open, 2017, Oct-06, Volume: 7, Issue:10

    Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Clinical Protocols; Cyclopropanes; Female; Humans; Imiquimod; Immunotherapy; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Research Design; Skin Neoplasms; Treatment Outcome; Young Adult

2017
Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2014, Volume: 20, Issue:2

    Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Melanoma; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Skin Neoplasms; Tomography, Optical Coherence; Treatment Outcome

2014
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
    Journal of immunology (Baltimore, Md. : 1950), 2008, Jul-01, Volume: 181, Issue:1

    Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antibody Formation; Antigens, Neoplasm; Biopsy; Cancer Vaccines; Epitope Mapping; Erythema; Female; Humans; Imiquimod; Immunization; Male; Melanoma; Membrane Proteins; Middle Aged; Pilot Projects; Toll-Like Receptor 7

2008
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
    The British journal of dermatology, 2008, Volume: 159, Issue:3

    Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Biomarkers; Female; Flow Cytometry; Humans; Imiquimod; Immunotherapy, Active; Injections, Intralesional; Interferon Inducers; Interferon-gamma; Interleukin-2; Interleukin-4; Interleukin-5; Longitudinal Studies; Lymphocyte Activation; Male; Melanoma; Middle Aged; Skin Neoplasms; Statistics, Nonparametric; Th1 Cells; Th2 Cells

2008
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Imiquimod; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Skin Ulcer; Treatment Outcome

2012
Immunomodulation by imiquimod in patients with high-risk primary melanoma.
    The Journal of investigative dermatology, 2012, Volume: 132, Issue:1

    Topics: Administration, Topical; Adult; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Immunologic Factors; Male; Melanoma; Pilot Projects; Preoperative Care; Prospective Studies; Risk Factors; Skin; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Treatment Outcome

2012
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
    European journal of immunology, 2012, Volume: 42, Issue:11

    Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Flow Cytometry; Freund's Adjuvant; Humans; Imiquimod; Immunologic Memory; Ligands; Lipids; MART-1 Antigen; Melanoma; Nanoparticles; Oligodeoxyribonucleotides; Skin Neoplasms; Statistics, Nonparametric; Toll-Like Receptor 7; Toll-Like Receptor 9

2012
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
    The Journal of investigative dermatology, 2004, Volume: 122, Issue:5

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biopsy; Cell Line, Tumor; fas Receptor; Humans; Imidazoles; Imiquimod; Melanocytes; Melanoma; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2004
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
    Cancer immunity, 2004, Sep-23, Volume: 4

    Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cytokines; Dendritic Cells; Female; Humans; Imiquimod; Immunotherapy, Active; Male; MART-1 Antigen; Melanoma; Membrane Proteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Peptide Fragments

2004
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    The British journal of dermatology, 2007, Volume: 156, Issue:2

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Ointments; Skin Neoplasms; Treatment Outcome

2007
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
    British journal of cancer, 1996, Volume: 74, Issue:9

    Topics: Adult; Aged; Aminoquinolines; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imiquimod; Interferon Inducers; Interferons; Kidney Neoplasms; Male; Melanoma; Middle Aged

1996

Other Studies

100 other study(ies) available for imiquimod and Melanoma

ArticleYear
New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Quinoxalines; Structure-Activity Relationship

2009
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission.
    Journal for immunotherapy of cancer, 2021, Volume: 9, Issue:10

    Topics: Administration, Topical; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imiquimod; Melanoma; Middle Aged; Mouth; Treatment Outcome

2021
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statem
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022, 07-04, Volume: 32, Issue:7

    Topics: Carcinoma in Situ; Cidofovir; Colposcopy; Female; Genital Neoplasms, Female; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Paget Disease, Extramammary; Pregnancy; Skin Neoplasms; Vulvar Neoplasms

2022
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statem
    Journal of lower genital tract disease, 2022, Jul-01, Volume: 26, Issue:3

    Topics: Carcinoma in Situ; Colposcopy; Female; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Paget Disease, Extramammary; Pregnancy; Skin Neoplasms; Squamous Intraepithelial Lesions; Vulvar Neoplasms

2022
Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia.
    Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 350

    Topics: Cell Line, Tumor; Chitosan; Humans; Hydrogels; Hyperthermia, Induced; Imiquimod; Immunotherapy; Melanoma; Nanoparticles

2022
A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma.
    Biomaterials science, 2022, Nov-22, Volume: 10, Issue:23

    Topics: Adjuvants, Immunologic; Animals; Antigens; Cancer Vaccines; Humans; Imiquimod; Immunity; Immunotherapy; Magnesium; Melanoma; Mice

2022
    Drug development and industrial pharmacy, 2022, Volume: 48, Issue:11

    Topics: Apoptosis; Humans; Imiquimod; Lipids; Liposomes; Melanoma; Necrosis; Skin

2022
Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine.
    Journal for immunotherapy of cancer, 2023, Volume: 11, Issue:2

    Topics: Adjuvants, Immunologic; Cancer Vaccines; Humans; Imiquimod; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Melanoma; T-Lymphocytes; Toll-Like Receptor 7

2023
Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
    Journal of drugs in dermatology : JDD, 2023, 05-01, Volume: 22, Issue:5

    Topics: Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Melanoma, Cutaneous Malignant; Retrospective Studies; Skin Neoplasms; Treatment Outcome

2023
Non-surgical management of primary invasive melanoma.
    The Journal of dermatological treatment, 2021, Volume: 32, Issue:6

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms; Treatment Outcome; Tretinoin

2021
Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2020, Volume: 43, Issue:4

    Topics: Biological Products; Biopsy; Combined Modality Therapy; Disease Management; Herpesvirus 1, Human; Humans; Imiquimod; Immune Checkpoint Inhibitors; Kidney Transplantation; Male; Melanoma; Middle Aged; Oncolytic Virotherapy; Treatment Outcome

2020
Actinic keratosis: Treatment with imiquimod 3.75%-A comparative study between patients with previous in situ melanoma, patients with invasive melanoma and patients with negative history of melanoma.
    Dermatologic therapy, 2020, Volume: 33, Issue:4

    Topics: Aminoquinolines; Humans; Imiquimod; Keratosis, Actinic; Melanoma; Skin Neoplasms

2020
In transit melanoma and imiquimod: A case of disease progression.
    Dermatologic therapy, 2020, Volume: 33, Issue:4

    Topics: Aminoquinolines; Antineoplastic Agents; Disease Progression; Humans; Imiquimod; Melanoma; Skin Neoplasms

2020
New pectin-based hydrogel containing imiquimod-loaded polymeric nanocapsules for melanoma treatment.
    Drug delivery and translational research, 2020, Volume: 10, Issue:6

    Topics: Animals; Cell Line, Tumor; Humans; Hydrogels; Imiquimod; Melanoma; Nanocapsules; Pectins; Swine

2020
Lesional therapies for in-transit melanoma.
    Journal of surgical oncology, 2020, Volume: 122, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate

2020
In lieu of penectomy: complete resolution of penile melanoma in situ with topical imiquimod and tretinoin.
    International journal of dermatology, 2021, Volume: 60, Issue:8

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms; Tretinoin

2021
Dermoscopic Features of Giant Molluscum Contagiosum in a Patient with Acquired Immunodeficiency Syndrome.
    Acta dermatovenerologica Croatica : ADC, 2020, Volume: 28, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Adult; Child, Preschool; Female; Humans; Imiquimod; Melanoma; Molluscum Contagiosum; Skin Neoplasms

2020
Novel Treatment of In-Transit Metastatic Melanoma With Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream.
    Journal of drugs in dermatology : JDD, 2021, May-01, Volume: 20, Issue:5

    Topics: Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Curettage; Electrocoagulation; Humans; Imiquimod; Male; Melanoma; Skin Cream; Skin Neoplasms

2021
Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2017, Volume: 43, Issue:8

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms; Treatment Outcome

2017
9-Phenanthrol enhances the generation of an CD8
    Journal of dermatological science, 2017, Volume: 87, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Calcium; Cell Degranulation; Cell Movement; Dendritic Cells; Humans; Imiquimod; Immunity, Innate; Mast Cells; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phenanthrenes; Protein Kinase Inhibitors; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; TRPM Cation Channels; Vaccination; Xenograft Model Antitumor Assays

2017
Topical Imiquimod for Melanoma In Situ? A Word of Caveat.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2018, Volume: 44, Issue:4

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Melanoma; Skin Neoplasms

2018
T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
    The Journal of investigative dermatology, 2018, Volume: 138, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Retinoids; Skin Neoplasms; T-Lymphocytes; Treatment Outcome

2018
Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma.
    The Journal of dermatology, 2018, Volume: 45, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Biopsy; Combined Modality Therapy; Cryosurgery; Dermatologic Surgical Procedures; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Immunotherapy; Melanoma; Skin; Skin Cream; Skin Neoplasms

2018
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
    Biomaterials, 2018, Volume: 170

    Topics: Animals; Antigen-Presenting Cells; Cancer Vaccines; Cell Death; Cell Line; Cell Line, Tumor; Cell Movement; Drug Synergism; Endocytosis; Endosomes; Imiquimod; Immunity, Innate; Immunization; Immunotherapy; Lymph Nodes; Magnetite Nanoparticles; Melanoma; Mice, Inbred C57BL; Nanotechnology; Neoplasms; Phospholipids; Poly I-C; Polyethylene Glycols

2018
Recurrence Patterns after Primary Excision of Invasive Melanoma with Melanoma
    The American surgeon, 2018, Aug-01, Volume: 84, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Male; Margins of Excision; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms

2018
Serial excision and imiquimod for lentigo maligna melanoma: a proposal for a combined treatment.
    Italian journal of dermatology and venereology, 2021, Volume: 156, Issue:Suppl. 1 t

    Topics: Combined Modality Therapy; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Skin Neoplasms

2021
Management of vulval melanoma in situ with imiquimod.
    The British journal of dermatology, 2019, Volume: 180, Issue:4

    Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Female; Humans; Imiquimod; Melanoma; Microscopy, Confocal; Treatment Outcome; Vulva; Vulvar Neoplasms

2019
An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
    Annals of plastic surgery, 2019, Volume: 82, Issue:4S Suppl 3

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Female; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm, Residual; Pilot Projects; Retrospective Studies; Skin Neoplasms

2019
Long-term outcomes of imiquimod-treated lentigo maligna: add on cryosurgery to induce inflammation and increase efficacy?
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:2

    Topics: Cryosurgery; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Inflammation; Melanoma; Skin Neoplasms

2020
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
    Cancer immunology research, 2013, Volume: 1, Issue:6

    Topics: Adult; Aminoquinolines; Anaphylaxis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Female; Guillain-Barre Syndrome; Humans; Imiquimod; Indoles; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sulfonamides; Vemurafenib

2013
[In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
    Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:2

    Topics: Administration, Cutaneous; Adult; Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Electrocoagulation; Facial Neoplasms; Fatal Outcome; Humans; Imiquimod; Interferon-alpha; Laser Therapy; Lasers, Gas; Leg; Lymphatic Metastasis; Male; Melanoma; Palliative Care; Remission Induction; Sentinel Lymph Node Biopsy; Skin Neoplasms

2014
Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells.
    Oncotarget, 2014, Mar-15, Volume: 5, Issue:5

    Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxyglucose; Drug Therapy, Combination; Gene Expression Regulation; Gene Silencing; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imiquimod; Keratinocytes; Lactams, Macrocyclic; Melanoma; Mice; Protein Biosynthesis; Protein Transport; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Toll-Like Receptor 7; Toll-Like Receptor 8; Transcription, Genetic; Up-Regulation

2014
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
    The Journal of investigative dermatology, 2014, Volume: 134, Issue:10

    Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Down-Regulation; Fibroblast Growth Factors; Humans; Imiquimod; Interleukin-8; Melanoma; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Ribonuclease, Pancreatic; Skin Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    European journal of immunology, 2014, Volume: 44, Issue:8

    Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7

2014
Use of imiquimod for residual acral melanoma.
    BMJ case reports, 2014, Aug-21, Volume: 2014

    Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Female; Follow-Up Studies; Foot Diseases; Humans; Imiquimod; Male; Melanoma; Melanoma, Cutaneous Malignant; Skin Cream; Skin Neoplasms; Treatment Outcome

2014
Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:1

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Foot; Humans; Imiquimod; Melanoma; Skin Neoplasms; Treatment Outcome

2015
Multifocal melanoma in situ of the penis treated with topical Imiquimod.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:3

    Topics: Adult; Aminoquinolines; Antineoplastic Agents; Biopsy; Humans; Imiquimod; Male; Melanoma; Penile Neoplasms; Penis

2016
Using topical imiquimod for the management of positive in situ margins after melanoma resection.
    Cancer medicine, 2015, Volume: 4, Issue:4

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome

2015
Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.
    Journal of dermatological science, 2015, Volume: 78, Issue:2

    Topics: Adenosine Triphosphate; Aminoquinolines; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Gene Silencing; Humans; Imiquimod; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Differentiation Factor 88; Phosphorylation; Protein Biosynthesis; Protein Serine-Threonine Kinases; Signal Transduction; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8

2015
Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:6

    Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Carcinoma in Situ; Chemotherapy, Adjuvant; Cohort Studies; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Skin Cream; Skin Neoplasms; Survival Rate; Treatment Outcome

2015
Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.
    Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:11

    Topics: Aminoquinolines; Animals; Cancer Vaccines; Cell Movement; Chemotaxis; Cytokines; Dendritic Cells; Humans; Imiquimod; Lymph Nodes; Matrix Metalloproteinase 9; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; T-Lymphocytes

2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Journal of the American Academy of Dermatology, 2015, Volume: 73, Issue:4

    Topics: Administration, Topical; Aminoquinolines; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Melanoma, Cutaneous Malignant; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Retinoids; Retrospective Studies; Risk Assessment; Skin Neoplasms; Treatment Outcome

2015
Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition.
    Journal of cellular and molecular medicine, 2016, Volume: 20, Issue:2

    Topics: Aminoquinolines; Apoptosis; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Humans; Imiquimod; JNK Mitogen-Activated Protein Kinases; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; NF-kappa B; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein

2016
Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
    The Journal of dermatology, 2016, Volume: 43, Issue:5

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Cryosurgery; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms

2016
Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
    The Journal of dermatological treatment, 2016, Volume: 27, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Eruptions; Female; Humans; Imiquimod; Indoles; Keratoacanthoma; Melanoma; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib

2016
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
    Melanoma research, 2016, Volume: 26, Issue:4

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Humans; Imiquimod; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms

2016
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
    Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:10

    Topics: Administration, Topical; Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Cell Movement; Cells, Cultured; Combined Modality Therapy; Cytokines; Enzyme-Linked Immunospot Assay; Female; Humans; Imiquimod; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Staging; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Toll-Like Receptor 7; Transcriptome; Vaccines, Subunit

2016
Topical imiquimod clears invasive melanoma.
    Cutis, 2016, Volume: 98, Issue:5

    Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Scalp; Skin Neoplasms

2016
Subungual Melanoma In Situ Treated With Imiquimod 5% Cream After Conservative Surgery Recurrence.
    Journal of drugs in dermatology : JDD, 2017, Mar-01, Volume: 16, Issue:3

    Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Humans; Imiquimod; Male; Melanoma; Nails; Neoplasm Recurrence, Local; Skin Cream; Skin Neoplasms; Toes

2017
Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2008, Volume: 34, Issue:9

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Mohs Surgery; Skin Neoplasms; Treatment Outcome

2008
Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2009, Volume: 7, Issue:6

    Topics: Aminoquinolines; Antineoplastic Agents; Head and Neck Neoplasms; Humans; Imiquimod; Male; Melanoma; Middle Aged; Remission Induction; Scalp; Skin Neoplasms; Treatment Outcome

2009
Progress of multiple cutaneous and subcutaneous melanoma metastases of the face during imiquimod treatment.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2009, Volume: 7, Issue:6

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Facial Neoplasms; Fatal Outcome; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms; Treatment Failure

2009
The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2009, Volume: 35, Issue:5

    Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Cheek; Female; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Scalp; Skin Neoplasms; Wound Healing

2009
[Diagnosis and treatment of non-melanoma skin neoplasm].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:4

    Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Imiquimod; Melanoma; Neoplasm Staging; Photochemotherapy; Prognosis; Skin Neoplasms

2009
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
    Journal of cutaneous pathology, 2010, Volume: 37, Issue:1

    Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Dermis; Female; Head and Neck Neoplasms; Humans; Imiquimod; Melanoma; Middle Aged; Skin Neoplasms; Subcutaneous Tissue; Treatment Outcome

2010
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2010, Jan-31, Volume: 39, Issue:1-3

    Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays

2010
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
    PloS one, 2010, May-13, Volume: 5, Issue:5

    Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; CD8-Positive T-Lymphocytes; Cell Proliferation; Dinucleoside Phosphates; Hydroquinones; Imiquimod; Immunoglobulin G; Immunotherapy; Injections, Subcutaneous; Killer Cells, Natural; Leukocyte Count; Lymphocyte Activation; Lymphocyte Depletion; Melanoma; Mice; Mice, Inbred C57BL; Pigmentation; Skin Neoplasms

2010
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
    Cellular & molecular immunology, 2010, Volume: 7, Issue:5

    Topics: Aminoquinolines; Animals; Cell Proliferation; Cells, Cultured; Cytotoxicity, Immunologic; Dendritic Cells; Imidazoles; Imiquimod; Immunization; Lymphocyte Activation; Melanoma; Mice; Mice, Inbred C57BL; Spleen; Toll-Like Receptor 7

2010
Post-surgical treatment of melanoma in situ of the vulva with imiquimod.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2010, Volume: 32, Issue:8

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Melanoma; Vulvar Neoplasms

2010
Lentiginous melanoma in situ treatment with topical imiquimod: need for individualized regimens.
    Archives of dermatology, 2010, Volume: 146, Issue:11

    Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Female; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms

2010
Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:3

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Disease Progression; Humans; Imiquimod; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms

2011
Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Melanoma research, 2011, Volume: 21, Issue:3

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Retinoids; Skin Neoplasms

2011
Re-inventing intratumoral immunotherapy for melanoma.
    Immunotherapy, 2011, Volume: 3, Issue:5

    Topics: Aminoquinolines; Antineoplastic Agents; BCG Vaccine; Cytokines; Humans; Imiquimod; Immunotherapy; Injections, Intralesional; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome

2011
[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:10

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Kaplan-Meier Estimate; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prognosis; Skin Neoplasms; Skin Ulcer

2011
Topical imiquimod in the treatment of two cutaneous melanocytomas in a dog.
    Veterinary dermatology, 2012, Volume: 23, Issue:2

    Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Imiquimod; Melanoma; Skin Neoplasms

2012
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:5

    Topics: Aminoquinolines; Antineoplastic Agents; Asymptomatic Diseases; Cryotherapy; Diagnostic Imaging; Evidence-Based Medicine; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Lymphatic Metastasis; Melanoma; Nail Diseases; Neoplasm Grading; Neoplasm Staging; Sentinel Lymph Node Biopsy; Skin Neoplasms

2011
Treatment of locally recurrent mucosal melanoma with topical imiquimod.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-20, Volume: 29, Issue:33

    Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Vaginal Neoplasms; Vulvar Neoplasms

2011
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
    Journal of immunology (Baltimore, Md. : 1950), 2012, Feb-15, Volume: 188, Issue:4

    Topics: Aminoquinolines; Cell Line, Tumor; Dendritic Cells; Humans; Imiquimod; Interferon Inducers; Interferon-alpha; Jurkat Cells; Melanoma; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9

2012
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:2

    Topics: Adaptive Immunity; Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL2; Dendritic Cells; Humans; Imiquimod; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Myeloid Differentiation Factor 88; Neoplasms, Experimental; Receptor, Interferon alpha-beta; Signal Transduction; Skin; Toll-Like Receptor 7

2012
Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:6

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Facial Neoplasms; Follow-Up Studies; Humans; Imiquimod; Male; Melanoma; Mohs Surgery; Skin Neoplasms

2012
Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:2

    Topics: Aged, 80 and over; Aminoquinolines; Anti-Infective Agents, Local; Antineoplastic Agents; Chemoradiotherapy; Drug Therapy, Combination; Gentian Violet; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms

2012
Clearance of invasive melanoma with topical imiquimod.
    Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:1

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Female; Frail Elderly; Humans; Imiquimod; Inflammation; Melanoma; Neoplasm Invasiveness; Skin; Skin Neoplasms

2013
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.
    The British journal of dermatology, 2002, Volume: 147, Issue:3

    Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Lymphatic Metastasis; Male; Melanoma; Skin Neoplasms

2002
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Dermatology (Basel, Switzerland), 2002, Volume: 205, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Skin Neoplasms

2002
Topical imiquimod in the treatment of metastatic melanoma to skin.
    Archives of dermatology, 2003, Volume: 139, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome

2003
Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod.
    Dermatology (Basel, Switzerland), 2003, Volume: 206, Issue:3

    Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms

2003
Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease.
    Archives of dermatology, 2003, Volume: 139, Issue:7

    Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Facial Neoplasms; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Melanoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Skin Neoplasms

2003
Locoregional cutaneous metastases of malignant melanoma and their management.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:2 Pt 2

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Lymphatic Metastasis; Male; Melanoma; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Skin Neoplasms; Treatment Outcome

2004
[Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2

    Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Antineoplastic Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Time Factors

2004
In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.
    The British journal of dermatology, 2004, Volume: 150, Issue:4

    Topics: Administration, Topical; Aged; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Gene Expression Regulation; Humans; Imiquimod; Interferon-alpha; Kisspeptins; Matrix Metalloproteinases; Melanoma; Neovascularization, Pathologic; Proteins; Skin Neoplasms; Tissue Inhibitor of Metalloproteinase-1; Tumor Suppressor Proteins; Vascular Endothelial Growth Factors

2004
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod.
    Journal of immunology (Baltimore, Md. : 1950), 2004, Sep-01, Volume: 173, Issue:5

    Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Movement; Dendritic Cells; Flow Cytometry; Imiquimod; Inflammation; Melanoma; Mice; Skin; Spleen

2004
Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches.
    Archives of dermatology, 2004, Volume: 140, Issue:9

    Topics: Aminoquinolines; Biopsy, Needle; Facial Neoplasms; Follow-Up Studies; Humans; Imiquimod; Immunohistochemistry; Male; Melanoma; Microscopy, Confocal; Middle Aged; Mohs Surgery; Neoplasm Staging; Risk Assessment; Sampling Studies; Sensitivity and Specificity; Skin; Skin Neoplasms; Treatment Outcome

2004
Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:12 Pt 2

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Imiquimod; Melanoma; Neck; Skin Neoplasms

2004
Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser.
    The British journal of dermatology, 2005, Volume: 152, Issue:2

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Humans; Imiquimod; Laser Therapy; Male; Melanoma; Skin Neoplasms

2005
Minimizing surgery in skin cancer treatment. A new test looks for cancer in the lymph nodes during melanoma surgery, while a topical cream helps people with another form of skin cancer avoid the knife.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:2

    Topics: Adjuvants, Immunologic; Aminoquinolines; Antibodies, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Basal Cell; Humans; Imiquimod; Lymphatic Metastasis; Melanoma; Skin Neoplasms

2005
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Journal of cutaneous pathology, 2005, Volume: 32, Issue:4

    Topics: Adjuvants, Immunologic; Aminoquinolines; Breast Neoplasms; Carcinoma, Basal Cell; Chemotaxis, Leukocyte; Female; Humans; Imiquimod; Interferon Type I; Lymphocytes; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Receptors, Chemokine; Receptors, CXCR3; Signal Transduction; Skin; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptors

2005
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    International journal of dermatology, 2005, Volume: 44, Issue:5

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Drug Administration Schedule; Facial Neoplasms; Female; Humans; Imiquimod; Male; Melanoma; Skin Neoplasms; Treatment Outcome

2005
[Imiquimod for the treatment of skin metastases of melanoma].
    Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:8

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Skin Neoplasms

2005
Advances in the understanding and treatment of melanoma -- Keystone Symposium.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:3

    Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasm Staging; Thalidomide; Toll-Like Receptors

2006
TOLLing away in Brazil.
    Nature immunology, 2006, Volume: 7, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Aminoquinolines; Animals; Antineoplastic Agents; Antiprotozoal Agents; Brazil; Carcinoma, Basal Cell; Condylomata Acuminata; Diaminopimelic Acid; Drosophila melanogaster; Drosophila Proteins; Gene Expression Regulation; Gram-Negative Bacteria; Humans; Imiquimod; Immunity, Innate; Infections; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Melanoma; Mice; Models, Immunological; Molecular Structure; Peptidoglycan; Protozoan Infections; Radiation Chimera; RNA Helicases; Signal Transduction; Skin Diseases; Skin Neoplasms; Substrate Specificity; Toll-Like Receptor 7; Toll-Like Receptors

2006
Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream.
    The British journal of dermatology, 2006, Volume: 155, Issue:1

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Female; Humans; Imiquimod; Melanoma; Precancerous Conditions; Vulvar Neoplasms

2006
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
    The British journal of dermatology, 2006, Volume: 155, Issue:2

    Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Fatal Outcome; Female; Humans; Imiquimod; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms

2006
In situ photoimmunotherapy: a tumour-directed treatment for melanoma.
    The British journal of dermatology, 2006, Volume: 155, Issue:6

    Topics: Aged; Aminoquinolines; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Imiquimod; Infrared Rays; Laser Therapy; Lung Neoplasms; Male; Melanoma; Middle Aged; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms; Toll-Like Receptors; Treatment Outcome

2006
Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa.
    The Lancet. Oncology, 2006, Volume: 7, Issue:12

    Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Female; Humans; Imiquimod; Melanoma; Mouth Mucosa; Mouth Neoplasms; Skin Neoplasms

2006
Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
    The American Journal of dermatopathology, 2007, Volume: 29, Issue:3

    Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Biomarkers, Tumor; Bowen's Disease; Carcinoma in Situ; Carcinoma, Basal Cell; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Inflammation; Keratosis; Male; Melanoma; Middle Aged; Skin Neoplasms

2007
Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma.
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:5

    Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Female; Imiquimod; Immunotherapy, Adoptive; Injections, Intralesional; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms

2007
Treatment of locally metastatic melanoma: a novel approach.
    Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:8

    Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imiquimod; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nicotinic Acids; Skin Neoplasms; Treatment Outcome

2007
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008, Volume: 28, Issue:4

    Topics: Aminoquinolines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Dendritic Cells; Humans; Imiquimod; Interferon Type I; Leukocytes, Mononuclear; Lung; Melanoma; Mice; Neoplasms; Oligodeoxyribonucleotides; Quinolines; Subcellular Fractions; Sulfonamides; Toll-Like Receptor 7; Toll-Like Receptor 9

2008
Topical imiquimod treatment of a cutaneous melanoma metastasis.
    Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Female; Humans; Imiquimod; Melanoma; Middle Aged; Skin Neoplasms; Treatment Outcome

2000
[Initial success with topical immunomodulators. A creme for skin cancer? (interview by Renate Jackle)].
    MMW Fortschritte der Medizin, 2001, May-24, Volume: 143, Issue:21

    Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Humans; Imiquimod; Melanoma; Neoplasms, Radiation-Induced; Ointments; Radiodermatitis; Skin Neoplasms; Treatment Outcome

2001